[go: up one dir, main page]

AR062987A1 - Metodo de estabilizacion de famotidina - Google Patents

Metodo de estabilizacion de famotidina

Info

Publication number
AR062987A1
AR062987A1 ARP070104238A ARP070104238A AR062987A1 AR 062987 A1 AR062987 A1 AR 062987A1 AR P070104238 A ARP070104238 A AR P070104238A AR P070104238 A ARP070104238 A AR P070104238A AR 062987 A1 AR062987 A1 AR 062987A1
Authority
AR
Argentina
Prior art keywords
famotidine
wax
composition
pharmaceutical industry
present
Prior art date
Application number
ARP070104238A
Other languages
English (en)
Inventor
Armenta Maria Elena Garcia
Ochoa Victor Guillermo Alvarez
Murillo Josefina Santos
Original Assignee
Espinosa Abdala Leopoldo De Jesus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Espinosa Abdala Leopoldo De Jesus filed Critical Espinosa Abdala Leopoldo De Jesus
Publication of AR062987A1 publication Critical patent/AR062987A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

La presente está relacionada con la industria farmacéutica. y más específicamente con la industria farmacéutica de la manufactura de productos a partir de la famotidina. La presente describe un método para estabilizar en pH alcalino a un inhibidor de receptores de H2 tal como lo es la Famotidina mediante un proceso de microencapsulacion utilizando como materiales formadores de la película productos en cera o de naturaleza polimérica, tal como lo es la cera microcristalina, cera montánica, cera ozoquerita, chitosan o alginato de sodio. Las ventajas de la presente invencion con respecto de los procedimientos del estado de la técnica es el de hacer posible con su aplicacion de una composicion de famotidina que resista más el medio de la composicion en la que se encuentra y los efectos que pudiera tener la composicion en el tracto digestivo. Sobre todo cuando esta sustancia se incluye en una composicion conteniendo antiácido alcalino.
ARP070104238A 2006-09-25 2007-09-25 Metodo de estabilizacion de famotidina AR062987A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA06010972A MXPA06010972A (es) 2006-09-25 2006-09-25 Proceso para estabilizacion de famotidina.

Publications (1)

Publication Number Publication Date
AR062987A1 true AR062987A1 (es) 2008-12-17

Family

ID=39230698

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104238A AR062987A1 (es) 2006-09-25 2007-09-25 Metodo de estabilizacion de famotidina

Country Status (8)

Country Link
EP (1) EP2085079A2 (es)
AR (1) AR062987A1 (es)
BR (1) BRPI0717425A2 (es)
CL (1) CL2007002760A1 (es)
CO (1) CO6160290A2 (es)
CR (1) CR10685A (es)
MX (1) MXPA06010972A (es)
WO (1) WO2008039052A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351059B (es) * 2012-08-17 2017-09-29 Laboratorios Senosiain S A De C V Star Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
MA46713A (fr) * 2016-11-01 2019-09-11 Johnson & Johnson Consumer Inc Forme posologique pharmaceutique orale liquide comprenant un antagoniste du récepteur h2 à l'histamine et un antiacide
EP3687502B1 (en) * 2017-09-29 2023-06-07 Johnson & Johnson Consumer Inc. Solid simethicone particles and dosage form thereof
US11433024B2 (en) 2018-04-27 2022-09-06 Johnson & Johnson Consumer Inc. Liquid oral pharmaceutical dosage form
EA202191063A1 (ru) 2018-10-18 2021-07-12 Джонсон энд Джонсон Консьюмер Инк. Новая дозированная форма
CA3156028A1 (en) * 2019-09-27 2021-04-01 Johnson & Johnson Consumer Inc. Gel-chewable dosage form

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ503823A (en) * 1997-10-27 2002-04-26 Sumitomo Pharma Amide derivatives and their use in treating retinal neurodegenerative disorders
US20050053655A1 (en) * 2003-09-05 2005-03-10 Pharmaceutical Industry Technology And Development Center Rapid disintegrating tablets (RDTs) for pharmaceutical use and method for preparing the same

Also Published As

Publication number Publication date
EP2085079A2 (en) 2009-08-05
WO2008039052A8 (es) 2009-05-07
BRPI0717425A2 (pt) 2013-11-12
WO2008039052A3 (es) 2008-06-19
CL2007002760A1 (es) 2008-04-25
CR10685A (es) 2009-05-22
CO6160290A2 (es) 2010-05-20
MXPA06010972A (es) 2009-04-17
WO2008039052A2 (es) 2008-04-03

Similar Documents

Publication Publication Date Title
AR062987A1 (es) Metodo de estabilizacion de famotidina
JOP20200148B1 (ar) تركيبة عقار ذو إطلاق متأخر
WO2009100263A3 (en) Oral care product and methods of use and manufacture thereof
EP2486793A3 (en) Stable S-(+)-abscisic acid liquid and soluble granule formulations
DE602006004719D1 (de) Verfahren zur herstellung von cellulosesulfat mit verbesserten eigenschaften
BRPI1003281A2 (pt) Composição e método para maquilar um substrato queratínico
EA201170053A1 (ru) Способ получения и сушки твердого разагилина в форме основания
IN2012DN00570A (es)
CL2007002031A1 (es) Composicion farmaceutica que comprende una droga antiparasitaria insoluble en agua y un portador soluble en agua, en donde la droga se encuentra en la forma nano-dispersa; dispersion acuosa que la comprende; proceso para prepararla, util para el tratamiento o profilaxis de la malaria.
MX364560B (es) Proceso de microencapsulacion y producto.
MX2010004341A (es) Producto para el cuidado oral y metodo de uso y fabricacion del mismo.
AR070105A1 (es) Composicion de detergente para lavanderia que comprende un glicosilo hidrolasa y un agente benefico que contiene particulas de suministro
EA201170483A1 (ru) Твердая фармацевтическая композиция
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
CR9411A (es) Agentes secuestrantes para micronutrientes fertilizantes
WO2010116382A3 (en) Stable pharmaceutical compositions of diclofenac
WO2006134361A3 (en) Agricultural composition
CO6630089A2 (es) Composicion de encapsulamiento de liberacion rapida
WO2009142428A3 (en) Pharmaceutical composition for the treatment of premature ejaculation
EA201100287A1 (ru) Композиция ропинирола
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
WO2009150257A3 (en) Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
EA201170180A1 (ru) Фармацевтические композиции соматотропных гормонов
EP2063268A4 (en) FLUORESCENCE SEMICONDUCTOR MICROPARTICLES, METHOD FOR THE PRODUCTION OF THE MICROPARTICLE, FLUORESCENT MARKING AGENT FOR A BIOLOGICAL SUBSTANCE WITH USE OF THE MICROPARTICLE AND BIOLOGICAL IMAGING PROCESS WITH USE OF THE MICROPARTICLE
WO2007002881A3 (en) Compositions and methods of use of derivatized flavanols

Legal Events

Date Code Title Description
FA Abandonment or withdrawal